GlassScriptPhysician profile
Barbara Levine-Blase
NPI 1376523597
$729.78
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $59.93 · 2021: $303 · 2022: $246.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $120.01 | 2019 | |
| Novo Nordisk INC | $88.28 | 2021-2022 | |
| Abbvie INC. | $67.61 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $60.44 | 2021 | |
| Lilly USA, LLC | $58.16 | 2021-2022 | |
| Esperion Therapeutics, INC. | $56.68 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $53.32 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $45.48 | 2021-2022 | |
| Astellas Pharma US INC | $42.83 | 2020-2021 | |
| Glaxosmithkline, LLC. | $34.90 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $26.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.77 | 2021 | |
| Abbott Laboratories | $17.32 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.91 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Levine-Blase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.